Literature DB >> 26912431

Smaller Agents for Larger Therapeutic Indices: Nanoscale Brachytherapy with 177Lu-Labeled Gold Nanoparticles.

Emily B Ehlerding1, Weibo Cai2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26912431      PMCID： PMC4891258          DOI： 10.2967/jnumed.116.173278

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  15 in total

1.  Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients.

Authors:  Hisahito Endo; Takuro Saito; Akira Kenjo; Mika Hoshino; Masanori Terashima; Tetsu Sato; Takayuki Anazawa; Takashi Kimura; Takao Tsuchiya; Atsushi Irisawa; Hiromasa Ohira; Takuto Hikichi; Tadayuki Takagi; Mitsukazu Gotoh
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-07       Impact factor: 7.027

Review 2.  18F-FDG PET and PET/CT in the evaluation of cancer treatment response.

Authors:  Simona Ben-Haim; Peter Ell
Journal:  J Nucl Med       Date:  2009-01       Impact factor: 10.057

3.  In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

Authors:  Youn H Kim; Dita Gratzinger; Cameron Harrison; Joshua D Brody; Debra K Czerwinski; Weiyun Z Ai; Anjali Morales; Farah Abdulla; Leon Xing; Daniel Navi; Robert J Tibshirani; Ranjana H Advani; Bharathi Lingala; Sumit Shah; Richard T Hoppe; Ronald Levy
Journal:  Blood       Date:  2011-11-01       Impact factor: 22.113

4.  The use of gold nanoparticles to enhance radiotherapy in mice.

Authors:  James F Hainfeld; Daniel N Slatkin; Henry M Smilowitz
Journal:  Phys Med Biol       Date:  2004-09-21       Impact factor: 3.609

5.  A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.

Authors:  A Nakao; H Kasuya; T T Sahin; N Nomura; A Kanzaki; M Misawa; T Shirota; S Yamada; T Fujii; H Sugimoto; T Shikano; S Nomoto; S Takeda; Y Kodera; Y Nishiyama
Journal:  Cancer Gene Ther       Date:  2010-11-19       Impact factor: 5.987

Review 6.  Accelerated partial breast irradiation trials: diversity in rationale and design.

Authors:  Mariella Mannino; John Yarnold
Journal:  Radiother Oncol       Date:  2009-01-27       Impact factor: 6.280

7.  Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries.

Authors:  Nagi S El Saghir; Alexandru Eniu; Robert W Carlson; Zeba Aziz; Daniel Vorobiof; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

8.  The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer.

Authors:  P E Lindsay; V V Moiseenko; J Van Dyk; J J Battista
Journal:  Phys Med Biol       Date:  2003-02-21       Impact factor: 3.609

9.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

10.  Brachytherapy in accelerated partial breast irradiation (APBI) - review of treatment methods.

Authors:  Janusz Skowronek; Magdalena Wawrzyniak-Hojczyk; Kinga Ambrochowicz
Journal:  J Contemp Brachytherapy       Date:  2012-09-29
View more
  2 in total

Review 1.  Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy.

Authors:  Baljeet Seniwal; Velaphi C Thipe; Sukhvir Singh; Telma C F Fonseca; Lucas Freitas de Freitas
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

2.  A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225.

Authors:  Evangelia-Alexandra Salvanou; Dimitris Stellas; Charalampos Tsoukalas; Barbara Mavroidi; Maria Paravatou-Petsotas; Nikolaos Kalogeropoulos; Stavros Xanthopoulos; Franck Denat; Gautier Laurent; Rana Bazzi; Stephane Roux; Penelope Bouziotis
Journal:  Pharmaceutics       Date:  2020-02-21       Impact factor: 6.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.